NEWS & EVENTS

Biodextris Appoints Dr. Behzad Mahdavi as Executive Chairman & Chief Commercial Officer Who: Dr. Behzad Mahdavi, Ph.D., MBA, NACD.DC — a biopharma industry veteran with over 25 years of senior leadership experience in CDMO and CRO sectors, including roles at Lonza and Catalent. What: He has been appointed Executive Chairman and will additionally serve as Chief Commercial Officer at Biodextris. Why: Dr. Mahdavi will spearhead the company’s global commercial expansion, leveraging his expertise in commercial innovation and international market development About Biodextris: Headquartered in Laval (Montréal), Québec, Biodextris is a rising Contract Development & Manufacturing Organization (CDMO) specializing in biologics and vaccine development, rooted in the legacy of GSK’s biologics and supported by ArchiMed private equity. For full details, you can read the original PR Newswire article here: https://www.prnewswire.com/news-releases/biodextris-appoints-dr-behzad-mahdavi-as-executive-chairman-to-lead-global-commercial-expansion-302472664.html

Learn about the strategic partnership between Aramis Biotechnologies and Biodextris to advance vaccine and biologics development.

Clean Biologics acquires Biodextris—bringing together expertise in biologics manufacturing and accelerating growth in CDMO services.

Biodextris inaugure de nouvelles installations à Laval pour renforcer son expertise en développement biologique.

Biodextris inaugurates its new Laval facility in Biotech City, expanding its capabilities in biologics development and manufacturing.

Discover Biodextris' new cGMP biomanufacturing and analytical facility. Check out our state-of-the-art capabilities.

Discover how Quality by Design (QbD) helps streamline biologics development, reduce costs, and improve product outcomes in complex CDMO environments.

Explore how a project-based CDMO collaboration model ensures better flexibility, transparency, and outcomes in biologics development.